Principal Financial Group Inc. bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,590 shares of the company’s stock, valued at approximately $70,000.
Several other large investors have also modified their holdings of ALT. North Star Investment Management Corp. acquired a new stake in Altimmune in the 1st quarter worth $31,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Altimmune in the first quarter valued at about $44,000. Russell Investments Group Ltd. raised its holdings in shares of Altimmune by 1,150.9% in the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after buying an additional 3,959 shares during the last quarter. TFO Wealth Partners LLC bought a new stake in Altimmune during the 1st quarter worth about $51,000. Finally, Horizon Wealth Management LLC acquired a new stake in Altimmune in the 2nd quarter valued at about $66,000. 78.05% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at $289,510.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.
Altimmune Stock Performance
Altimmune (NASDAQ:ALT – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. During the same quarter in the prior year, the company earned ($0.32) EPS. As a group, sell-side analysts predict that Altimmune, Inc. will post -0.54 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on ALT shares. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 target price on shares of Altimmune in a research report on Friday, June 21st. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.80.
Check Out Our Latest Research Report on Altimmune
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Articles
- Five stocks we like better than Altimmune
- Investing In Automotive Stocks
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Industrial Products Stocks Investing
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Technology Stocks Explained: Here’s What to Know About Tech
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT – Free Report).
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.